Exelixis Inc - Company Profile
Powered by 
All the sales intelligence you need on Exelixis Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Exelixis Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Exelixis Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on Exelixis Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| US20230382917A1 | Application | Heterocyclic adenosine receptor antagonists | C07D487/04; C07D487/14; C07D513/14 | November 30, 2023 |
| US20230382867A1 | Application | Crystalline solid forms of n-{4-[(6,7-DIMETHOXYQUINOLIN-4-YL)oxy]phenyl}-n'-(4-FLUOROPHENYL) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use | C07B2200/13; C07D215/22; C07D215/233 | November 30, 2023 |
| JP2023168551A | Application | 抗ｒｏｒ抗体構築物 | A61K2039/505; A61K45/06; A61P35/00; C07K16/2803; C07K16/2809; C07K16/2818; C07K16/2878; C07K16/468; C07K2317/24; C07K2317/31; C07K2317/35; C07K2317/522; C07K2317/524; C07K2317/526; C07K2317/55; C07K2317/77; C07K2317/92; C07K2317/94 | November 24, 2023 |
| US20230374024A1 | Application | Compounds for the treatment of kinase-dependent disorders | C07D239/88; C07D403/04; C07D403/12; C07D405/12; C07D487/04 | November 23, 2023 |
| WO2023224961A1 | Application | Cancer therapy using a combination of a cdk7 inhibitor with an oral serd | A61K31/137; A61K31/38; A61K31/40; A61K31/4155; A61K31/437; A61K31/4741; A61K31/4745 | November 23, 2023 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer